Divestitures, New Offerings, Strategic Partnerships and Management Appointments to Deliver Quality Patient Care - Research Report on Quest Diagnostics, Covance, Alere, PAREXEL, and TearLab
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, October 4, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Quest Diagnostics Inc. (NYSE: DGX), Covance Inc. (NYSE: CVD), Alere Inc. (NYSE: ALR), PAREXEL International Corporation (NASDAQ: PRXL), and TearLab Corporation (NASDAQ: TEAR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Quest Diagnostics Inc. Research Report
On October 1, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced that it has completed the sale of its Enterix colorectal cancer screening test business to Clinical Genomics Technologies Pty Ltd. on September 30, 2013. Based on a preliminary analysis, the Company expects to record a loss of approximately $25 million after tax, or $0.17 per share, for Q3 2013 on sale of the Enterix business. The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/05ba_DGX]
Covance Inc. Research Report
On September 25, 2013, Covance Inc. (Covance) announced the launch of external laboratory management services, a new offering that provides biopharmaceutical companies with a comprehensive management solution for external laboratory testing associated with clinical trials. These services include laboratory selection and qualification, auditing, vendor management, contracting and data cleaning. Gary Paul, Global Director of Quality Assurance for Covance Central Laboratory Services said, "As the pioneer of the central laboratory model, this new offering further establishes Covance's position as a leader and innovator in clinical trials testing and sets a new industry standard for the management of data quality." The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5691_CVD]
Alere Inc. Research Report
On September 23, 2013, Alere Inc. (Alere) announced that it has partnered with Malaria No More on its Power of One campaign. The campaign will raise funds to deliver life-saving tests and treatment to children in Africa. Under this campaign, Malaria No More, a non-profit organization to end malaria deaths, will collaborate with Alere on the initiative to fight against Malaria. "As the world's leading provider of rapid diagnostic tests for malaria, Alere is deeply committed to working with partners such as Malaria No More to prevent deaths from this devastating disease, one that particularly strikes young children," said Avi Pelossof, Global President of Infectious Disease at Alere. "We encourage people to support the Power of One campaign and help end malaria deaths in sub-Saharan Africa." The Full Research Report on Alere Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5da1_ALR]
PAREXEL International Corporation Research Report
On September 24, 2013, PAREXEL International Corp. (Parexel) announced the schedule of the release of its Q1 FY 2014 financial results. The Company has set the earnings release date of October 29, 2013, Tuesday, after the close of the stock market. Parexel will also host a conference call and live webcast at 10:00 a.m. ET on October 30, 2013 to discuss the results. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/067b_PRXL]
TearLab Corporation Research Report
On October 1, 2013, TearLab Corp. (TearLab) announced that Seph Jensen has been appointed as the Company's President and Chief Operating Officer. The Company reported that Mr. Jensen has a strong track record in sales and marketing, operations and general management success in the ophthalmic industry. "Seph is a seasoned leader with a strong track record of delivering operational excellence and profitable growth," commented TearLab's Chief Executive Officer, Elias Vamvakas. "I have tremendous confidence in his ability to help us build our sales infrastructure and sharpen our execution. Most importantly, he is exceptionally qualified to help us continue to build a unique and powerful partnership within the eye care community." The Full Research Report on TearLab Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/58d3_TEAR]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.www.AnalystsCorner.com
SOURCE Analysts' Corner
More by this Source
Strategic Collaborations, Clinical Studies, Regulatory Update, and Other Corporate Announcements - Research Report on OncoMed, Auxilium Pharma, BioTelemetry, Progenics Pharma, and Ambit Biosciences
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.